The latest news from Retina UK. Please use the filters to find the articles which interest you.
Featured
A huge thank you to everyone who completed our 2025 sight loss survey. This year we received over 600 responses. It follows similar surveys in 2019 and 2022 which led directly to the introduction of our Unlock Genetics and Discover Wellbeing resources, as well as shaping our work with the professional community who support people with inherited sight loss.
Featured
Catch up on our BBC Lifeline Appeal from November 2025.
Featured
Researchers who received funding from Retina UK have carried out experimental gene therapy that is reported to have led to ‘life changing improvements’ to sight for four children with inherited sight loss.
SparingVision have announced this week that they have dosed all participants in their phase 1/2 PRODYGY clinical trial for SPVN06, a gene agnostic therapy aimed at slowing disease progression in Retinitis Pigmentosa (RP).
Please find below a research opportunity for people with confirmed stargardt disease.
Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.
SpliceBio has begun the dose-expansion portion of their phase 1/2 clinical trial of SB-007, a dual adeno-associated viral vector gene therapy for Stargardt disease.
Opus Genetics has launched an early-stage clinical trial of OPGx-MERTK, an investigational gene therapy for MERTK-related Retinitis Pigmentosa (RP), a condition that causes progressive vision loss due to photoreceptor degeneration.
During RP awareness month, Paul Bacon has shared how his diagnosis has impacted his life and shared messages about how non visually impaired people can support those living with inherited sight loss. To learn more about inherited sight loss please take the time to read Paul's story.
